Oppenheimer Asset Management Inc. Purchases 145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Oppenheimer Asset Management Inc. increased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 3.4% during the 3rd quarter, Holdings Channel reports. The firm owned 4,457 shares of the biotechnology company’s stock after buying an additional 145 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $557,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Prime Capital Investment Advisors LLC raised its holdings in shares of Sarepta Therapeutics by 3.0% during the third quarter. Prime Capital Investment Advisors LLC now owns 8,654 shares of the biotechnology company’s stock valued at $1,081,000 after acquiring an additional 249 shares in the last quarter. Platform Technology Partners raised its holdings in Sarepta Therapeutics by 15.2% in the 3rd quarter. Platform Technology Partners now owns 2,462 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 325 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Sarepta Therapeutics by 21.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 300 shares during the period. WCM Investment Management LLC boosted its stake in shares of Sarepta Therapeutics by 32.5% during the 3rd quarter. WCM Investment Management LLC now owns 10,917 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 2,680 shares in the last quarter. Finally, Crossmark Global Holdings Inc. increased its position in shares of Sarepta Therapeutics by 16.1% during the third quarter. Crossmark Global Holdings Inc. now owns 7,161 shares of the biotechnology company’s stock valued at $894,000 after buying an additional 994 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 1.9 %

Shares of Sarepta Therapeutics stock opened at $106.62 on Wednesday. The firm has a fifty day moving average price of $122.85 and a 200 day moving average price of $132.00. The stock has a market cap of $10.18 billion, a PE ratio of 85.30 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a 1 year low of $78.67 and a 1 year high of $173.25.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SRPT. StockNews.com downgraded Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday. Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $205.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This trade represents a 14.99 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.